Category Archives: Central Gov.

CPC Organization Department and NHC Issue Revised Management Measures for Public Hospital Leadership – Eight‑Chapter Framework Resets Qualifications, Terms, Assessment and Exit Rules Nationwide

Policy Snapshot

Item	Detail
Authorities	Organization Department of the CPC Central Committee; National Health Commission (NHC)
Document	Management Measures for Leaders in Public Medical Institutions (2026 revision)
Revision History	Enacted 13 Jan 2017 (Organization Dept + former NHFPC); revised 22 Jul 2026; published 12 Aug 2026
Scope	Leadership team members of public hospitals run by governments at county level and above, public institutions, social groups and other social organizations; SOE‑run public hospitals apply the measures by reference
Structure	8 chapters, 35 articles – general provisions, qualifications, selection & appointment, assessment, career development & incentives, supervision, exit, supplementary provisions
Effective Date	From date of publication (12 Aug 2026)

Qualification & Selection Framework

Baseline Qualifications: Generally a bachelor’s degree or above; 5+ years of medical/health or related management experience — 10+ years for leaders of tertiary hospitals; deputy‑to‑principal promotion requires 2+ years in a deputy role, and lower‑principal to higher‑deputy requires 3+ years.
Technical‑to‑Management Tracks: Professionals from medical, pharmacy, nursing, technical and research posts must hold corresponding professional technical appointments — e.g., senior or 5+ years associate‑senior titles for Grade 4+ management posts and for tertiary hospital presidents and business‑line deputies; relaxed thresholds apply in hardship and remote areas.
Sourcing Channels: Selection generally via internal recommendation or external dispatch, with competitive appointment and open recruitment permitted to widen the talent pool; presidents and business deputies generally come from the medical/health sector.
Appointment Modes: Tenure by election, appointment or engagement (聘任制) — leaders produced through open selection generally serve under the engagement system, with flexible pay and term arrangements allowed.

Tenure, Assessment & Compensation

Term Limits: Terms of 3–5 years; continuous service in the same post generally capped at 10 years (extendable with approval); leaders are expected to serve out at least one full term.
Public‑Welfare‑Oriented Targets: Term objectives embed medical quality and safety, cost control, public‑welfare duties, lawful management, medical ethics and Party building; tertiary hospitals add digital‑intelligent construction and discipline/team development; TCM hospitals must reflect traditional Chinese medicine’s distinctive advantages.
Assessment Ratings: Teams graded excellent/good/average/poor (excellent ≤ 30 % of teams assessed); individuals graded excellent/qualified/basically qualified/unqualified (excellent ≤ 25 %), with cascading caps when a team is rated average or poor.
Time Commitment & Pay: Leaders must devote ≥ 4/5 of statutory working time to hospital management; compensation ties to assessment and keeps a reasonable ratio to average staff income — directly linking leader income to hospital economic revenue is strictly prohibited, with an annual salary system permitted where conditions allow.
Development & Rotation: Full training coverage every 5 years; structured exchanges across hospital tiers and regions — urban tertiary hospitals with county hospitals, eastern with central/western institutions — aligned with Healthy China resource‑balancing goals.

Supervision, Recusal & Exit

Expanded Oversight: Inspection tours and audits target procurement, drugs and devices, infrastructure, service outsourcing, medical insurance fund use, income distribution, title appointments and “ghost payroll” issues, alongside democratic centralism and “three majors and one large” decision‑making compliance.
Recusal Rules: Leaders must recuse themselves where interests involve directly supervised graduate students, their own academic teams or other conflicts affecting impartial duty.
Exit Mechanisms: Age‑limit retirement with possible extension for outstanding principals; adjustment of leaders deemed unfit for current posts (e.g., medical ethics violations, poor handling of major emergencies); a resignation system explicitly guards against “revolving door” and “escape‑style resignation” problems, while exiting leaders may transition to professional technical roles.

Market Impact & Outlook

Professionalization of Hospital Management: Engagement‑based appointments, 5‑year training cycles and professional‑track transitions signal a deliberate build‑out of a professional public hospital leadership corps.
Anti‑Profit Reinforcement: The hard ban on tying leader pay to hospital revenue strengthens the public‑welfare orientation — constraining volume‑driven revenue behavior with downstream effects on device and drug utilization patterns.
Talent Redistribution: Mandatory rotation between tertiary, county, eastern and western hospitals operationalizes the policy goal of expanding and sinking quality medical resources.
Compliance Bar Rises: The detailed supervision catalogue raises accountability for hospital leadership — and by extension for suppliers’ interactions with procurement, IT and infrastructure decision‑makers.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding implementation of the revised management measures, including leadership selection, assessment outcomes and compensation reforms. Actual execution depends on interpretation by the Organization Department and NHC, local implementation rules and individual institutional practice, and may differ materially from current expectations.-China Health Reform Pulse

Policy Source: https://www.nhc.gov.cn/wjw/mtbd/202609/7e830145ff3144d8b8609b5616c09793.shtml

NMPA’s CMDE Opens Public Consultation on Revised Guidelines for Tuberculosis Drug‑Resistance Gene Mutation Detection Reagents – 2026 Revision Signals Tightened Review Standards for Molecular TB Diagnostics in China

Consultation Snapshot

Item	Detail
Agency	CMDE, under the National Medical Products Administration (NMPA), China
Action	Public solicitation of opinions on a revised draft registration review guideline
Document	Guidelines for Registration and Review of Mycobacterium tuberculosis Complex Resistance Gene Mutation Detection Reagents (2026 Revised Edition, Draft for Comments)
Purpose	Standardize technical review requirements; guide applicants in preparing and writing registration dossiers
Notice Date	16 September 2026
Comment Deadline	15 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Notice	cmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

Product Scope: The guideline covers in vitro diagnostic reagents that detect resistance‑associated gene mutations in the Mycobacterium tuberculosis complex — molecular tests used to identify drug‑resistant TB (including multidrug‑resistant TB) directly from clinical specimens, in contrast to slower culture‑based drug susceptibility testing.
Revision, Not First Edition: CMDE has revised the existing guideline rather than issuing an inaugural document, indicating updates to review expectations accumulated from prior registration experience. The specific changes were not disclosed in the notice; the full draft is available for download from CMDE.
Submission Format: Comments must be filed via the official feedback form (Annex 2) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
Contacts: Cheng Xi, Liu Rongzhi (+86‑10‑86452580, +86‑10‑86452532; chengxi@cmde.org.cn, liurz@cmde.org.cn).

Sector Background

Molecular Resistance Detection: Gene mutation assays — typically PCR‑based — identify resistance‑conferring mutations (e.g., in rpoB for rifampicin resistance) within hours, enabling rapid treatment decisions versus weeks for phenotypic testing.
Public Health Priority: China remains among the countries with the highest TB and multidrug‑resistant TB burden globally, making fast, accurate resistance detection central to national TB control programs and the WHO End TB Strategy.
IVD Registration Environment: CMDE technical review guidelines define the evidentiary expectations (analytical performance, clinical studies, reference comparators) for IVD registration in China; public consultation is the standard step before finalization.

Market Impact & Outlook

Regulatory Predictability: A revised, codified standard reduces dossier ambiguity for IVD sponsors and shortens the review cycle for resistance‑detection assays targeting the M. tuberculosis complex.
Competitive Landscape: Domestic molecular diagnostics developers — alongside global IVD players active in China’s TB testing market — should benchmark their clinical evidence and performance claims against the 2026 draft before launching new registrations or renewals.
Portfolio Implications: Manufacturers with existing TB resistance‑detection products should assess whether current dossiers and performance data meet the revised expectations, particularly on mutation coverage and clinical concordance requirements.
Participation Window: Stakeholders have until 15 October 2026 to influence the final guideline — an opportunity to raise practical issues on reference standards, comparator selection, and multi‑center clinical study design.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of the draft guideline, and its potential impact on in vitro diagnostic registration in China. The draft is subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916144510144.html

NMPA’s CMDE Opens Public Consultation on Draft Review Guidelines for AI Multi‑Disease Decision Devices and Deep Brain Stimulation Systems – Standardized Review Pathways Signal Next Phase of China MedTech Regulation

Consultation Snapshot

Item	Detail
Agency	CMDE, under the National Medical Products Administration (NMPA), China
Action	Public solicitation of opinions on two draft technical review guidelines
Document 1	AI‑assisted multi‑disease decision‑making medical devices – clinical evaluation & registration review
Document 2	Implantable deep brain stimulation (DBS) systems – clinical evaluation & registration review
Notice Date	15 September 2026
Comment Deadline	14 October 2026, via email using the prescribed feedback form and subject‑line naming convention
Original Notice	cmde.org.cn (published 16 September 2026)

Guideline Scope & Submission Channels

Document 1 – AI Multi‑Disease Decision Devices: Targets software‑based devices that assist clinical decision‑making across multiple diseases, defining clinical evaluation and registration review requirements. Detailed technical provisions were not disclosed in the notice itself; the full draft is available for download from CMDE.
Document 2 – Implantable DBS Systems: Sets out clinical evaluation and registration review requirements for implantable deep brain stimulation systems, a class of active implantable neurostimulation devices.
Submission Format: Comments must be filed via the official feedback form (Annex 3) by email, with subject lines and file names formatted as “Guideline name – feedback + organization name.”
Contacts – AI Guideline: Wang Zehua, Jiang Yan, Dong Zheng (wangzh@cmde.org.cn, jiangyan@cmde.org.cn, dongzheng@cmde.org.cn).
Contacts – DBS Guideline: Cui Xinyue, Guo Jiaying, Jin Yaxi (cuixy@cmde.org.cn, guojy@ydcmdei.org.cn, jinyx@cmde.org.cn) — with a Shanghai contact number indicating involvement of CMDE’s Yangtze River Delta branch.

Sector Background

AI as a Medical Device (SaMD): China has progressively built a review framework for AI‑enabled diagnostic software. Extending dedicated guidance to multi‑disease decision support reflects the regulator’s response to algorithms that synthesize patient data across indications rather than addressing a single disease — a materially more complex clinical evaluation problem.
Deep Brain Stimulation: DBS is an established implantable therapy for movement disorders such as Parkinson’s disease, with China’s market served by both global manufacturers (Medtronic, Abbott, Boston Scientific) and domestic players (PINS Medical, SceneRay).
Guideline System: CMDE technical review guidelines standardize registration dossiers and evaluation criteria; public consultation is the customary step before guidelines are finalized and take effect.

Market Impact & Outlook

Regulatory Clarity: Codified evaluation criteria for AI decision‑support software and implantable neurostimulators reduce approval uncertainty for developers and shorten pre‑submission negotiations.
AI‑MedTech Landscape: Sponsors of multi‑disease AI platforms — including hospital‑affiliated developers and health‑AI startups — should benchmark their clinical evidence strategies against the draft before the final guideline lands.
Neuromodulation Standardization: A dedicated DBS guideline aligns China’s review expectations with the maturity of its neurostimulation market, benefiting both multinationals and domestic manufacturers pursuing registration or next‑generation product iterations.
Participation Window: Industry stakeholders have until 14 October 2026 to shape the final requirements — an opportunity to flag practical concerns on clinical evaluation design, real‑world evidence, and post‑market obligations.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, the finalization of draft guidelines, and their potential impact on medical device registration in China. The drafts are subject to revision based on public feedback, and actual requirements, effective dates, and review outcomes may differ materially.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916105408164.html